Kornimate/medical-research-clean huggingface dataset:
shalamar institute of health sciences

Conditions: Effect of Didactic Intervention Regarding (DASH) on Hypertension

Summary: effect of didactic intervention regarding dietary approach to stop hypertension (dash) on hypertensive patients blood pressure, knowledge and attitude at a tertiary hospital of lahore

objective: to explore the effect of didactic intervention regarding dietary approach to stop hypertension (dash) on hypertensive patients blood pressure, knowledge and attitude. study design: randomized controlled trial place and duration of study: punjab institute of cardiology (pic) lahore. from june 2018 to oct 2018. methodology: seventy volunteers aged 20-60 years attending regularly outpatient department at punjab institute of cardiology lahore, with systolic \> 130 mm hg, diastolic \> 80 mm hg were selected and assigned into 2 groups, i.e. intervention and control, by simple random lottery method. for twelve weeks, only intervention group were given dash education. both groups were checked for dash knowledge, attitude, and systolic diastolic blood pressure, before and after education session. pre-tested questionnaire was used for demographic, attitude and knowledge data collection.

Eligibility criteria:
inclusion criteria: * hypertensive patient aged 20-60 years attending regularly at punjab institute of cardiology outpatient department lahore * systolic \> 130 mm hg * diastolic \> 80 mm hg. exclusion criteria: * less than 20 years age * patient diagnosed with secondary hypertension * any mental and physical ailment that may interfere the intervention like deafness and blindness.
a study of cp-4126 in patients with advanced pancreatic cancer

Conditions: Advanced Adenocarcinoma of Pancreas

Summary: the main objective of this study is to assess the biological activity of cp-4126 in patients with advanced pancreatic cancer. in addition, the correlation between hent1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmed advanced pancreatic cancer\* * not eligible for curative resection * performance status (ecog) 0-2 * estimated life expectancy of at least 12 weeks * age ≥ 18 years * adequate haematological and biological functions: * neutrophils ≥ 1.5 x 109/l * platelets \> 100.0 x 109/l * hb ≥ 10 g/dl * ast/alt and alkaline phosphatase (alp) ≤ 2.5 x institutional upper limit of normal (uln), if liver metastases * ast/alt ≤ 5 x institutional uln and alp ≤ 4 x institutional uln * bilirubin ≤ 1.5 times institutional uln, if liver metastases ≤ 3 x institutional uln * serum creatinine ≤ 1.5 times institutional uln * signed informed consent exclusion criteria: * prior chemotherapy for metastatic disease * symptomatic brain metastases * participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study * requirement of concomitant treatment with a non-permitted medication, including high doses of vitamins and alternative drugs * history of allergic reactions to gemcitabine or egg * presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection) * presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance * pregnant or breastfeeding women * absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for three months after last treatment * known positive status for hiv * any reason why, in the investigator's opinion, the patient should not participate in the study. * drug or alcohol abuse * prior radical resection, but exploratory laparotomy as well palliative (e.g bypass) surgery are allowed

Keywords: pancreas advanced adenocarcinoma cp-4126
allocentric memory in ms and resting state functional mri

Conditions: Multiple Sclerosis

Summary: the goals of this study are to 1. investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among ms subjects when compared to controls. 2. determine which cognitive test variable will be most strongly associated with self and informant reports of cognition. 3. determine which mri metric will be most strongly related to neuropsychological test performance 4. determine the degree to which allocentric visual memory is related to functional connectivity on fmri.

this is a cross-sectional, case-control, observational experimental design. the study will enroll subjects with multiple sclerosis (ms) and age/gender matched on a battery of neuropsychological cognitive tests and self-report measures of cognition.

Eligibility criteria:
inclusion criteria: * 18-55 years old * right handed * capacity to provide informed consent and sign consent * diagnosis of relapsing remitting ms that meets the revised mcdonald criteria (2010) within the last 10 years * edss 0- 5.5 exclusion criteria: * diagnosis of primary progressive ms * contraindications for mri * subjects required to take medications known to either benefit or adversely affect cognition at the time of testing and impact neuroimaging * non-ms neurological disorders * other medical or psychiatric disorders likely to affect cognitive performance * active immunodeficiency, chronic infections, or history or progressive multifocal leukoencephalopathy * individuals with severe level of depression on the bdi-ii or severe anxiety on the bai * ms subjects who are actively experiencing acute exacerbation in symptoms and they must be at least 4 weeks free of steroid medication, are currently taking a chemotherapy agent, or have changed medication in the last two months * subjects who fail symptom validity measures during neuropsychological testing will be excluded
high power short duration ablation compared to moderate power long duration ablation for pulmonary vein isolation

Conditions: Paroxysmal Atrial Fibrillation

Summary: high power short duration ablation compared to moderate power long duration ablation for pulmonary vein isolation: safety and acute procedural outcome


Eligibility criteria:
inclusion criteria: * symptomatic, documented, drug-resistent paroxysmal atrial fibrillation * effective oral anticoagulation exclusion criteria: * any prior left atrial ablation procedure * presence of left atrial thrombus * secondary atrial fibrillation due to electrolyte imbalance or thyroid disease * any prior oesophageal or gastric surgery
multi-parametric magnetic resonance imaging for prostate cancer patients

Conditions: Prostate Cancer

Summary: this is a pilot study of implement multi-parametric mr imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

the study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Eligibility criteria:
inclusion criteria: * histologically confirmed prostate adenocarcinoma exclusion criteria: * patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering
association between cancer and sarcoidosis

Conditions: Sarcoidosis; Cancer

Summary: the purpose of this study is to develop a clinical dataset of sarcoidosis patients with a diagnosis of cancer who are categorized by date of birth, sex, race/ethnicity, clinical information, laboratory and imaging information, time of sarcoidosis onset, cancer type and treatment, time of cancer diagnosis, stage and grade.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of sarcoidosis following cancer * granulomatous reaction must be proven by pathology exclusion criteria: . aged younger than 18 years old.

Keywords: sarcoidosis, cancer, paraneoplastic, treatment, outcome
transanal versus laparoscopic-assisted transanal through in the management of hirschsprung's disease

Conditions: Pediatric Disorder; Hirschprung's Disease

Summary: the goal of this clinical trial is to compare the surgical and functional outcomes of pure transanal endorectal pull-through (taerpt) and laparoscopic-assistance endorectal pull-through (laerpt) in pediatric patients presented with hirschsprung's disease between 3 months and 18 years old. the main questions our study aims to answer are: * does post-operative continence differs between the two groups? * does post-operative constipation differs between the two groups? * does post-operative soiling differs between the two groups * does post-operative enterocolitis differs between the two groups? * do post-operative complications differ between the two groups? if there is a comparison group: researchers will compare between pure transanal endorectal pull-through (taerpt) and laparoscopic-assistance endorectal pull-through (laerpt) to see if there is a difference in post-operative continence, constipation, soiling, enterocolitis or complications. participants will be divided into two groups; 40 patients will be treated by taerpt and included in group a and 30 patients will be treated by laerpt and included in group b.

introduction: one-stage treatment of endorectal pull-through for hirschsprung's disease could be approached through a complete transanal approach or with the assistance of laparoscopy. our study aims to compare the surgical and functional outcomes of pure transanal endorectal pull-through (taerpt) and laparoscopic-assistance endorectal pull-through (laerpt). material \& methods: this retrospective study included 70 pediatric patients presented with hirschsprung's disease to elshatby university hospital. 40 patients were treated by taerpt and included in group a and 30 patients were treated by laerpt and included in group b. the two groups were compared as regards the operative data as well as the post-operative outcomes including the time of passage of stools, time of tolerating oral feeding, the duration of hospital stay, and the development of any early postoperative complications. also, the number of bowel habits, constipation, enterocolitis, abdominal distension, anastomotic stricture, and continence were assessed.

Eligibility criteria:
inclusion criteria \* pediatric patients with age range between 3 months and 18 years old presented with hirschsprung's disease who were confirmed to have this condition by contrast enema and/or rectal biopsy. exclusion criteria: * patients with previous colostomy.
cold water immersion does not reduce knee joint position sense in healthy participants: a randomised cross-over trial

Conditions: Knee Joint Position Sense

Summary: the aim of this project is to assess the effect of cold water immersion on knee joint re-positional sense in healthy subjects. cryotherapy, in the form of cold water immersion, had previously been shown to improve athletic performance however, debate exists within the existing literature regarding whether proprioception, in the form or joint position sense, is effected post treatment. null hypothesis (h0): water immersion has no effect on joint position sense (jps). alternate hypothesis (h1): water immersion has an effect on joint position sense.

this was a prospective, randomised, cross-over design where volunteers acted as their own controls. the volunteers were immersed at two temperatures (detailed below) and these sessions were separated by six to ten days. the order of the testing was randomly assigned using a random number generator. ethical approval of the design of this trial was gained from the university of limerick's research ethics committee and signed informed consent was gained from each participant before any data collection took place.

Eligibility criteria:
inclusion criteria: * healthy subjects between the ages of 18 and 40 who complete both a par-q test and sign an informed consent form. exclusion criteria: * potential subjects who do not complete a par-q questionnaire or provide written consent. subjects with any ankle or knee injuries in the past twelve months. * students who have a recent history of ear or vestibular conditions. * subjects who will not be available to attend all sessions. * subjects who are under the age of 18 or over the age of 40. * subjects who aren't comfortable with being blind-folded or videotaped during testing. * those who are sensitive to cold exposure or show signs of a contraindication to cryotherapy.

Keywords: cryotherapy joint position sense proprioception pre cooling knee injury physical therapy modalities physical therapy techniques weightbearing nonweightbearing randomised control trial
pushing and manual perineal protection techniques

Conditions: Perineal Tear; Episiotomy Extended by Laceration; Labor Complication

Summary: perineal trauma during vaginal delivery is very common, especially in countries with a high prevalence of episiotomy. perineal traumas can range from tears limited to the skin, subcutaneous and vaginal mucosa to severe tears involving the anal sphincter and rectal mucosa. perineal trauma is associated with short-term morbidities such as bleeding, infection, pain, edema. besides, it may cause long-term morbidities such as urinary incontinence, fecal incontinence, dyspareunia, a decrease in quality of life, a need for surgery, and psychosocial problems. moreover, it is associated with an increase in national healthcare costs and malpractice cases. for these reasons, some measures to reduce the frequency of perineal trauma have been discussed for many years. pushing techniques applied in the second stage of labor and manual perineum protection techniques applied during fetal expulsion are among these. current data are insufficient to make definitive recommendations. in this study, it was aimed to compare different pushing and perineal protection techniques in the second stage of labor.


Eligibility criteria:
inclusion criteria: * nulliparity * 37-40 weeks of gestation * singleton pregnancy * vertex presentation * risk-free pregnancy * estimated fetal weight 2500-4000 g * in the first stage of birth * amniotic membranes are intact * adequate knowledge of written and spoken turkish exclusion criteria: * cesarean delivery need * need for labor induction * need for operative delivery (vacuum, forceps) * need for obstetric analgesia * kristaller maneuver * perineal preparation during pregnancy (perineal massage in the last month of pregnancy, etc.) * vulvo-vaginal infection * vulvar severe varicose veins * postpartum atony * non-compliance with research follow-up criteria * covid-19 positivity * non-compliance with the procedure of the group involved * neuropsychiatric and other diseases that cause understanding, speech, and expression disorders

Keywords: episiotomy obstetric labor complications perineum
adding of naxitamb in induction therapy for high risk neuroblastoma

Conditions: Neuroblastoma; GD2 Antibody (Naxitamab)

Summary: to explore the efficacy of adding anti-gd2 immunotherapy (naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. to investigate wether anding naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.


Eligibility criteria:
inclusion criteria: neuroblastoma patients who meet certain criteria are eligible for enrollment in the following stages of diagnosis: 1. children with newly diagnosed stage 4 neuroblastoma according to the international neuroblastoma staging system (inss) who meet the following criteria are eligible for enrollment: i. age \> 18 months (\> 547 days) regardless of biological characteristics; or ii. age 12-18 months (365-547 days), with one of the following three unfavorable biological characteristics (mycn amplification, pathological type of poor histopathological prognosis, and/or dna index = 1); or iii. mycn amplification (mycn signal increase \> 4 times compared to reference signal) regardless of age or other biological characteristics. 2. children with newly diagnosed stage 3 inss neuroblastoma who meet the following criteria are eligible for enrollment: i. mycn amplification (mycn signal increase \> 4 times compared to reference signal) regardless of age or other biological characteristics; or ii. age \> 18 months (\> 547 days), with pathological type of poor histopathological prognosis regardless of mycn status. 3. children with newly diagnosed stage 2a/2b inss neuroblastoma with mycn amplification (mycn signal increase \> 4 times compared to reference signal) regardless of age or other biological characteristics. the subject must be aged ≤ 21 years at the time of initial diagnosis, and must be aged \> 12 months at the time of enrollment. exclusion criteria: infants less than 1 year old, those aged 12-18 months, inss stage 4, and all inss stage 3 patients with favorable biological characteristics (i.e., non-amplified mycn, good pathological histopathological prognosis, and dna index \>1) are not eligible. subjects who have received immunosuppressive treatment (excluding local steroids) within the last 4 weeks prior to enrollment. subjects who are currently receiving any investigational drug. any other medical condition that, in the opinion of the investigator, may interfere with the interpretation of results or affect the subject's ability to provide informed consent, the legal guardian's ability to provide informed consent, and the subject's cooperation and participation in the study, including but not limited to malabsorption syndrome, mental illness, or substance abuse. subjects with significant comorbidities (any serious medical condition unrelated to cancer or its treatment that is not covered by the detailed exclusion criteria and is expected to interfere with the investigation drug(s) action or significantly increase the severity of the trial treatment toxicity)
special drug use surveillance of vonoprazan for "prevention of recurrence of gastric/duodenal ulcer in patients receiving non-steroidal anti-inflammatory drugs: long-term use"

Conditions: A History of Gastric or Duodenal Ulcers

Summary: the purpose of this study is to investigate the safety and efficacy of long-term administration of vonoprazan tablets (takecab tablets) for up to 12 months in the routine clinical setting in patients receiving non-steroidal anti-inflammatory drugs (nsaids).

the drug being tested in this study is called vonoprazan. vonoprazan is being tested to treat people who have a history of gastric or duodenal ulcers. this study will look at the safety and efficacy of long-term administration of vonoprazan tablets for up to 12 months in the routine clinical setting in patients receiving nsaids. the study will enroll approximately 1000 participants. • vonoprazan 10 mg this multi-center observational survey will be conducted in japan.

Eligibility criteria:
inclusion criteria: - participants with a history of gastric or duodenal ulcer exclusion criteria: * participants with gastric or duodenal ulcer at initiation of vonoprazan therapy * participants with active upper gastrointestinal haemorrhage at initiation of vonoprazan therapy * participants with a history of hypersensitivity to any ingredients of vonoprazan tablets * participants receiving atazanavir sulfate or rilpivirine hydrochloride
extension study to evaluate the safety of long-term use of relacorilant in patients with cushing syndrome

Conditions: Cushing Syndrome

Summary: this is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous cushing syndrome who successfully completed participation in a corcept-sponsored study of relacorilant and may benefit from continuing treatment.

this study is designed to allow continued therapy with relacorilant, a potent, selective glucocorticoid receptor (gr) antagonist in patients who have successfully completed participation of a corcept-sponsored study of relacorilant (referred to as the "parent" study). patients may qualify to enter this extension study if they complete their last treatment visit in their parent study and in the investigator's opinion will benefit from continued treatment. once-daily dosing with relacorilant may continue for patients who receive clinical benefits (as judged by the investigator) until relacorilant is commercially or otherwise available or the study is stopped by the sponsor. a patient's dose may be maintained, reduced, or increased based on individual response and tolerability.

Eligibility criteria:
inclusion criteria: * major inclusion criteria: * have completed a corcept-sponsored study of relacorilant in endogenous cushing syndrome with at least 80% compliance with the dosing schedule. * according to the investigator's opinion will benefit from continuing treatment with relacorilant exclusion criteria: * major exclusion criteria: * premature discontinuation from a relacorilant parent study. * has uncontrolled, clinically significant hypothyroidism or hyperthyroidism * has poorly controlled hypertension * has stage ≥ 4 renal failure

Keywords: cushing syndrome cushing disease cushing hypercortisolemia cushingoid type 2 diabetes impaired glucose intolerance hypertension adrenal corticotrophic hormone (acth) adrenocortical carcinoma primary pigmented nodular adrenal disease (ppnad) moon facies dorsocervical fat pad adrenal adenoma adrenal carcinoma adrenal autonomy cortisol
evaluation of the benefit and safety of localized tissue hydration in the management of chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the purpose of this study is to evaluate the benefit of localized tissue hydration associated with standard management of chronic common low back pain, in terms of improvement in the numerical verbal scale score at 6 months.

this is a proof-of-concept, single-center, prospective, interventional, non-randomized phase ii study designed to evaluate the benefit of 0.9% sodium chloride localized tissue hydration in patients with chronic common low back pain. the study corresponds to a clinical trial of a medicinal product in compliance with regulation (eu) n°536/2014. the study population is composed of patients suffering from chronic common low back pain for more than 3 months with a numerical verbal scale ≥ 5. patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard management including stage i and ii analgesics and physiotherapy in accordance with the recommendations of the french national authority for health.

Eligibility criteria:
inclusion criteria: * patient 18 years of age or older ; * patient with chronic, non-operated low-back pain operated for more than 3 months (verbal numerical scale ≥ 5); * chronic common lumbago not requiring surgical management surgical ; * lumbar mri performed as part of routine care and available available for the inclusion visit; * for women of childbearing age, use of a highly effective contraceptive method; * patient affiliated to a french health insurance scheme; * patient has signed an informed consent form. exclusion criteria: * pregnant or breast-feeding woman; * patient in accident at work ; * patient with radicular syndrome; * contraindication to magnetic resonance imaging or ct scan; * severe cases of hydric inflation and hydrosodic retention, particularly in cases of : * decompensated heart failure; * acute renal failure with oliguria or anuria; * decompensated liver failure; * pre-eclampsia/eclampsia. * hypochloremia ; * hypernatremia ; * patients of legal age subject to legal protection, guardianship, curatorship or deprived of liberty by judicial or administrative decision; * patient hospitalized without consent; * patient unable to answer a questionnaire; * patients who do not understand or speak french. exclusion period for inclusion in another study : included patients will not be allowed to participate in another interventional study during the entire follow-up period. the exclusion period is 8.5 months.